{
    "body": "What is the mechanism of action of abiraterone?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9876107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23199349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22672122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23344012"
    ], 
    "ideal_answer": [
        "Abiraterone acts by inhibiting cytochrome P450 17\u03b1-hydroxylase (CYP17A1), a critical step in androgen biosynthesis, thus leading to inhibition of androgen biosynthesis."
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4266316", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
    ], 
    "type": "summary", 
    "id": "5148b466d24251bc05000037", 
    "snippets": [
        {
            "offsetInBeginSection": 664, 
            "offsetInEndSection": 897, 
            "text": "The recognition of sustained androgen dependence of CRPC has led to the identification of more potent and selective inhibitors of androgen synthesis and androgen-receptor signaling, such as abiraterone and enzalutamide, respectively.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344012", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 566, 
            "offsetInEndSection": 743, 
            "text": "This review summarizes the rationale, mechanism of action and relevant clinical data of abiraterone acetate , an oral androgen biosynthesis inhibitor, in the management of CRPC.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199349", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 350, 
            "offsetInEndSection": 637, 
            "text": "Sipuleucel-T, an immunotherapeutic vaccine, is now available in the US for patients with non-metastatic CRPC and abiraterone, an oral enzyme inhibitor of androgen biosynthesis, as well as cabazitaxel, a cytotoxic chemotherapeutic, have been approved for the treatment of metastatic CRPC.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672122", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 141, 
            "text": "Abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 1) is a potent inhibitor (IC50 4 nM for hydroxylase) of human cytochrome P45017alpha.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9876107", 
            "endSection": "sections.0"
        }
    ]
}